ReviewHaematologica2014
Update on treatment of light chain amyloidosis.
Review in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.Blood · 2017Trial
- First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Trial
- Management of relapsed/refractory AL amyloidosis.Blood advances · 2026Review
- Systemic AA Amyloidosis Secondary to Chronic Bronchiectasis and Primary Immunodeficiency: A Case Report.Cureus · 2025Article
- Localized Amyloidosis of the Oral Cavity: A Rare Clinical Entity.Clinical case reports · 2025Article
- Advancements in Cardiac Amyloidosis Treatment.Biomedicines · 2024Review
- Management of tracheobronchial amyloidosis: a review of the literature.ERJ open research · 2024Article
- Research trends and hotspots evolution of cardiac amyloidosis: a bibliometric analysis from 2000 to 2022.European journal of medical research · 2023Review
- Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.JACC. CardioOncology · 2022Article
- Independent Prognostic Utility ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Article
- Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.Blood · 2021Article
- Clinical ApoA-IV amyloid is associated with fibrillogenic signal sequence.The Journal of pathology · 2021Article
- Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment.Journal of clinical medicine · 2021Article
- Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.Arquivos brasileiros de cardiologia · 2021Article
- Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report.World journal of clinical cases · 2019Article
- Hematological Malignancies and Arterial Thromboembolism.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019Review
- Management of cardiovascular risk in patients with multiple myeloma.Blood cancer journal · 2019Review
- Article
- Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis.American health & drug benefits · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Light chain amyloidosis is the most common type of amyloidosis as a consequence of protein misfolding of aggregates composed of amyloid fibrils. The clinical features are dependent on the organs involved, typically cardiac, renal, hepatic, peripheral and autonomic neuropathy and soft tissue. A tissue biopsy or fat aspirate is needed to confirm the presence/type of amyloid and prognostic tools are important in a risk stratified approach to treatment. Autologous stem cell transplant eligibility should be assessed at baseline, weighing the reversible or non-reversible contraindications, toxicity of treatment and chemotherapy alternatives available. Chemotherapy options include melphalan, thalidomide, bortezomib, lenalidomide, bendamustine in combination with dexamethasone. Many studies have explored these treatment modalities, with ongoing debate about the optimal first line and sequential treatment thereafter. Attaining a very good partial response or better is the treatment goal coupled with early assessment central to optimizing treatment. One major challenge remains increasing the awareness of this disease, frequently diagnosed late as the presenting symptoms mimic many other medical conditions. This review focuses on the treatments for light chain amyloidosis, how these treatments have evolved over the years, improved patient risk stratification, toxicities encountered and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.